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ABSTRACT: N-(5-Bromo-3-methoxypyrazin-2-yl)-5-chlorothiophene-2-sulfonamide 1 was identified as a hit in a CCR4 re-
ceptor antagonist high throughput screen (HTS) of a sub-set of the AstraZeneca compound bank. As a hit with a lead-like 
profile, it was an excellent starting point for a CCR4 receptor antagonist program and enabled the rapid progression through 
the Lead Identification and Lead Optimization phases resulting in the discovery of two bioavailable CCR4 receptor antag-
onist candidate drugs. 
The chemokine receptor family was originally identified 
in the 1990s and has since grown in number, complexity 
and range of biological functions. Originally thought to be 
simple cell chemo attractants, chemokines have since been 
shown to exhibit a broader range of functions covering in-
volvement in HIV-1 infection to hematopoiesis and control 
of cell growth.1,2  
CCR4 is a G protein-coupled receptor (GPCR) and is ac-
tivated by the CC chemokines, CCL22 (MDC: macrophage-
derived chemokine) and CCL17 (TARC: T-cell and activa-
tion-related chemokine),3 leading to cell activation and 
chemotaxis; it is expressed mainly by Th2 lymphocytes.4,5  
In keeping with a role for CCR4 in the orchestrated move-
ment of Th2 cells into the allergic lung, both CCL17 and 
CCL22 have been shown to be elevated in the human lung 
following allergen challenge.6 This potential role of CCR4 
in driving human allergic lung disease led to many phar-
maceutical companies attempting to identify CCR4 recep-
tor antagonists for the treatment of allergic rhinitis and 
asthma,7–14,15 but as yet no drug has been discovered (Figure 
1).16,17  
 
Figure 1: Structures of a selection of recently published CCR4 recep-
tor antagonists. 
In this communication we are disclosing our studies on 
the optimization of N-(5-bromo-3-methoxypyrazin-2-yl)-
5-chlorothiophene-2-sulfonamide 1 to afford two clinical 
candidates AZD-2098 (47) and AZD-1678 (49).  High 
throughput screening of the AstraZeneca Mixed Chemo-
kine Receptor Antagonist Compound library (~29,000 
compounds) using a hCCR4 Fluorescent Microvolume As-
say Technology (FMAT) cell binding assay identified com-
pound 118,19 as an inhibitor of labeled CCL22 binding to 
CCR4 (pIC50 7.2).20 Subsequently functional antagonism of 
1 was shown using an hCCR4 Fluorescence Imaging Plate 
Reader (FLIPR) intracellular calcium mobilization assay 
(pIC50 7.0) and a human primary Th2 cell chemotaxis assay 
(pIC50 6.7). 
 Table 1 Hit profile of pyrazine sulfonamide 1 
 
Biological Assay / test procedure  Compound 1 
hCCR4 Binding (pIC50)   7.2 ± 0.2 
hPPB (%)  >99.9 
Calc. WBP (pIC50)*  <4.2 
logD  1.1 
Solubility (mg/mL)  0.34 
human hepatocytes (µL/mL/106cells)  <0.2 
rat / mouse in vivo PK   
Cl (mL/min/kg)  0.1 / 0.1 
Vss (L/kg)  0.1 / 0.1 
T½ (h)  16 / 10 
Bioavailability (%)  45 / 86 
Rat / mouse CCR4 binding (pIC50)  8.3 / 8.3 
Rat / mouse PPB (%)  99.85 / 96.7 
*Calculated from the hCCR4 binding and %age PPB 
Compound 1 exhibited a good lead-like profile21 and was 
shown to be selective for the CCR4 receptor, through 
screening against an internal panel of chemokine receptors 
(e.g. CXCR1 & CXCR2, CCR1, CCR2b, CCR5, CCR7 & CCR8; 
inactive at 10 µM).  When screened against a large panel of 
receptors and enzymes (~120 screens at MDS-Pharma), 
weak or no activity was observed and therefore 1 was cho-
sen as a starting point for the CCR4 antagonist program. 
Compound 1 had good solubility (0.34 mg/mL), rat bioa-
vailability (F = 45%) and half-life (T½ ~16 h) when dosed in 
rat and a similar profile when dose in vivo in mouse.  This 
long half-life was accounted for by a very low clearance (0.1 
mL/min/kg), which counteracts the small volume of distri-
bution (Vss 0.1 L/kg). 
Compound 1 had very good cross-over with rat and 
mouse CCR4 receptors (both pIC50 8.3). Subsequently, this 
species cross-over was shown to be a general feature of the 
sulfonamide series (see Table 5), with the CCR4 receptor 
from all three species displaying very similar structural ac-
tivity relationships (SAR).  When corrected for plasma pro-
tein binding, the predicted rat whole blood potency of 1 
was pIC50 5.5 (rat ppb 99.85%) and for mouse 6.8 (mouse 
ppb 96.7%), giving 1 a suitable profile for use as a target 
validation tool for in vivo hypothesis testing.  
However, the calculated human whole blood potency 
(WBP) was very poor with predicted activity (pIC50) < 4.2 
(calculated from hCCR4 pIC50 7.2 and hPPB >99.9%).  
With a candidate drug requiring a WBP pIC50 ~ 6.0, the 
key issue was to increase WBP by a combination of increas-
ing CCR4 receptor affinity and lowering plasma protein 
binding,22 whilst maintaining all the other good features 
inherent in 1. The high plasma protein binding was at-
tributed to the acidic sulfonamide-NH (measured pKa 4.1) 
and the lipophilic nature of the molecule (measured logP 
4.4).  
The structure activity relationship (SAR) generated with 
respect to modification of the 5-chlorothiophene group is 
shown in Table 2. Removal of the 5-chloro substituent 2 
gave over a 10-fold drop in affinity, as did the isomeric un-
substituted thiophene 3. Addition of a chlorine to the 4-
position of the thienyl group also gave a reduction in affin-
ity (compare 4 with 1) whilst a large substituent (bromine 
or phenyl) in the 3-position was tolerated (compare 5 and 
6 with 1 and 2 respectively). The phenyl analogue 7 was 
similar to the two unsubstituted thiophenes in potency 
and introducing chlorine into the 2-, 3- or 4-positions of 
the phenyl sulfonamide ring (8, 9 and 10) gave an increase 
in binding relative to 7. The 6-substituted dichlorophenyl 
sulfonamides  (11-17) had a potency range of almost 3 log 
units, with the 3,5-dichlorophenylsulfonamide analogue 14 
having only weak activity  (pIC50 5.3) and the 2,3-dichloro-
phenylsulfonamide 16 being optimal  (pIC50 8.0), almost a 
log unit more potent than 1. Similar affinity was achieved 
with 3, 4-dichloro-2-thienyl (compare 18 and 17). A number 
of other di-substituted phenyl sulfonamides were 
screened, however no improvement in binding was seen 
(19-24 compare with 17).   Introduction of a nitrogen into 
the aromatic ring lead to dramatic reduction in potency 
(25) as did replacement of the aromatic ring with an alkyl 
group as illustrated with 26.  
Whilst an increase in affinity was achieved with com-
pounds 16 and 17, changing the 5-chlorothiophene group 
for 2, 3-dichlorophenyl did not significantly change the lip-
ophilicity. Consequently, the hPPB figures for these two 
compounds was also high (>99.9%). 
Table 2 Exploration of the 5-position of the pyrazine 
ring 
 
Example R X CCR4 pIC50a 
1 5-Chloro-2-thienyl Br 7.2 ± 0.2 
2 2-Thienyl Br 6.2 ± 0.2 
3 3-Thienyl Br 5.9 ± 0.1 
4 4,5-Dichloro-2-thienyl Br 6.0 ± 0.1 
5 3-Bromo-5-chloro-2-thienyl Br 7.4 ± 0.2 
6 3-Phenyl-2-thienyl Br 6.0 ± 0.1 
7 Phenyl Br 6.1 ± 0.1 
8 2-Chlorophenyl Br 6.8 ± 0.2 
9 3-Chlorophenyl Br 7.0 ± 0.2 
10 4-Chlorophenyl Br 6.9 ± 0.2 
11 2,6-Dichlorophenyl Br 6.2 ± 0.2 
12 2,5-Dichlorophenyl Br 5.5 ± 0.1 
13 2,4-Dichlorophenyl Br 6.9 ± 0.2 
14 3,5-Dichlorophenyl Br 5.3 ± 0.1 
15 3,4-Dichlorophenyl Br 6.7 ± 0.2 
16 2,3-Dichlorophenyl Br 8.0 ± 0.2 
 17 2,3-Dichlorophenyl Cl 7.9 ± 0.2 
18 3,4-Dichloro-2-thienyl Cl 8.1 ± 0.2 
19 2-Chloro-3-fluorophenyl Cl 7.8 ± 0.2 
20 3-Chloro-2-fluorophenyl Cl 7.1 ± 0.2 
21 3-Chloro-2-methylphenyl Cl 7.7 ± 0.2 
22 
2-Chloro-3-
(trifluoromethyl)phenyl 
Cl 7.2 ± 0.1 
23 3-Chloro-2-cyanophenyl Cl 7.2 ± 0.2 
24 3-Chloro-2-methylthiophenyl Cl 7.1 ± 0.2 
25 2,3-Dichloro-4-pyridyl Cl 5.0 ± 0.1 
26 Butyl Cl 5.5 ± 0.2 
a Potency is given as pIC50 values with n = ≥ 2 replicates. 
The exploration of the 3-position is shown in Table 3. In-
itially the atom linking the 3-substituent to the pyrazine 
ring was investigated.  Changing methoxy for methylthio, 
methylamino or ethyl (28, 29 and 30) gave a large drop in 
potency, establishing oxygen as the optimal atom with 
which to attach the 3-substituent to the pyrazine ring.  
Next, a small number of 3-alkoxy analogues were synthe-
sized (27, 31 and 32). In each case there was a substantial 
drop in potency relative to the parent methoxy-substituted 
compound (1 or 17). However, the 3-allyloxy analogue (33) 
maintained activity and with the 3-propargyloxy (34) ana-
logue affording a slight increase in activity. Further in-
creases in activity was obtained with 3-OCH2Aryl and 3-
OCH2heteroaryl (35, 36, 37 and 38), where substitution 
gave substantial increase in activity (pIC50 up to 9.5). Alt-
hough this SAR demonstrated how to improve on CCR4 af-
finity, the increase in lipophilicity associated with these 
changes did not address the plasma protein binding issue 
with hPPB >99.9% in each case. 
Table 3 Exploration of the 3-position of the pyrazine ring. 
Example R2 R3 R4 CCR4 receptor antagonism (pIC50)a 
27 OEt Br 5-Chloro-2-thienyl 6.7 ± 0.2 
28 SMe Br 5-Chloro-2-thienyl 5.5 ± 0.2 
29 NHMe Br 5-Chloro-2-thienyl <5.0* 
30 Et Br 5-Chloro-2-thienyl 5.3 ± 0.2 
31 OBu Cl 2,3-Dichlorophenyl 6.8 ± 0.1 
32 OCH2tBu Cl 2,3-Dichlorophenyl 5.1 ± 0.2 
33 OCH2CHCH2 Cl 2,3-Dichlorophenyl 7.8 ± 0.1 
34 OCH2CCH Cl 2,3-Dichlorophenyl 8.6 ± 0.2 
 
35 
 
Cl 2,3-Dichlorophenyl 
 
9.2± 0.3 
 
36 
 
Cl 2,3-Dichlorophenyl 
 
8.4 ± 0.2 
 
37 
 
Cl 2,3-Dichlorophenyl 
 
9.5 ± 0.2 
38 
 
Cl 2,3-Dichlorophenyl 7.9 ± 0.3 
a Potency is given as pIC50 values with n = ≥ 2 replicates. *44% inhibition at 10 µM 
In contrast to the 3-position, the exploration of the 5- and 6-positions on the pyrazine ring allowed for the discovery of 
compounds with increased activity combined with lower lipophilicity relative to 17 (Table 4).  
Table 4 Exploration of the 5- and 6- position of the pyrazine ring. 
 
Example X R5 R6 CCR4 receptor antagonism (pIC50)a LogP hPPB (%) Calc. WBP (pIC50) 
17 CH=CH Cl H 7.9 ± 0.2 4.1 >99.9 - 
39 CH=CH H Cl 8.1 ± 0.3 4.5 >99.9 - 
 40 CH=CH OEt H 7.9 ± 0.2 4.1 >99.9 - 
41 CH=CH SO2Me H 5.3 ± 0.2 - - - 
42 CH=CH Me H 7.4 ± 0.2 3.0 99.65 4.9 
43 CH=CH H Me 7.3 ± 0.3 - >99.8 - 
44 CH=CH CH2OH H 7.6 ± 0.2 2.1 96.2 6.2 
45 CH=CH CH2OH Cl 8.4± 0.2 3.2 99.6 6.0 
46 CH=CH CH2OH Me 7.4 ± 0.1 2.4 98.7 5.5 
47 CH=CH H H 7.8 ± 0.05 2.5 98.9 5.8 
48 S H H 7.7 ± 0.2 2.8 97.5 6.1 
49 CH=CH F H 8.6 ± 0.1 3.1 99.4 6.4 
50 CH=CH H F 8.4 ± 0.2 3.3 >99.8 - 
51 CH=CH F F 9.0 ± 0.3 - >99.8 - 
a Potency is given as pIC50 values with n = ≥ 2 replicates. 
A wide variety of substituents were tolerated in the 5- and 
6-positions and it was discovered that the percentage 
plasma protein binding was reduced by lowering the lipo-
philicity of the compounds, affording plasma protein bind-
ing below 99% for compounds of modest lipophilicity 
(logP < 3.0). For 44, 45, 47, 48 and 49, the calculated WBP 
(pIC50) of 5.8-6.4 was achieved. These met the candidate 
drug target profile set of WBP pIC50 ~ 6.0. Of these four 
compounds, 47 and 49 had the best overall profile for pro-
gression (Table 5). Compounds 47 and 49 demonstrated 
good selectivity for the CCR4 receptor when screened in-
house against a range of other chemokine receptors 
(CXCR1 & CXCR2, CCR1, CCR2b, CCR5, CCR7 & CCR8; all 
inactive at 10 µM) and little or no activity when screened 
against a large panel of receptors and enzymes (~120 
screens at MDS-Pharma). A pharmacokinetic profile com-
mensurate with once-daily oral administration enabled 
both compounds to progress as candidate drugs.23  
Table 5 Compound profiles of 47 and 49 
 
Screen 47 (R7 = H) 49 (R7 = F) 
hCCR4 pIC50 7.8 ± 0.05 (n = 11) 8.6 ± 0.1 (n = 10) 
hPPB (%) 98.9 99.4 
Calc. WBP (pIC50) 5.9 6.4 
logD 0.35 0.6 
Solubility (mg/mL) 1.5 1.3 
Human hepatocytes 
(µL/mL/106cells) 
<0.2 <1.0 
Species cross over   
Rat CCR4 pIC50 8.0 ± 0.27 (n = 3) 9.0 ± 0.1 (n = 3) 
Mouse  CCR4 pIC50 8.0 ± 0.04 (n = 3) 9.0 ± 0.1 (n = 3) 
Dog  CCR4 pIC50 7.6 ± 0.06 (n = 7) 8.5 ± 0.2 (n = 3) 
Rat/dog in vivo PK*   
Cl (mL/min/kg) 2.0/1.5 2.3/3.7 
Vss (L/kg) 0.2/0.1 0.2/0.2 
T½ (h) 1.7/1.0 2.5/0.5 
F (%) 100/100 100/100 
dose-to-man predic-
tion (mg/kg) UID 
1 0.1 
*PK studies conducted using 1% sodium bicarbonate solu-
tion at 9.0 Mol/kg (p.o.) or 3.0 Mol/kg (i.v.) 
The antagonist potency of 47 and 49 were assessed in a 
number of cell systems in which a response mediated by 
the human CCR4 receptor can be evoked by MDC or TARC 
and quantified using changes in intracellular calcium con-
centration or chemotaxis.  The cell systems used were a cell 
line (CHO) transfected with the human CCR4 receptor and 
human CD4+, CD45RA+ Th2 cells in 0.3% HSA.  Findings 
are summarized in Table 6.  The reduced potency in the 
presence of added protein is consistent with the drop-off 
predicted from plasma protein binding measurements.  
Both 47 and 49 demonstrated no agonist activity at con-
centrations up to 10 M. 
Table 6 Potency of 47 and 49 for inhibition of cellular 
responses mediated by the human CCR4 receptor 
Cell system Assay 
readout 
47  (pIC50 
mean ± 
SEM) 
49 (pIC50 
mean ± 
SEM) 
Inhibition of 
CCL22 Ca2+ re-
sponse 
MDC-
induced 
Ca2+flux 
7.5  0.04 
(n=3) 
(CHO cells 
expressing 
hCCR4) 
8.4 ± 0.1 
(n=4) 
(HEK cells 
expressing 
hCCR4) 
Inhibition of Th2 
cell CCL22 driven 
chemotaxis in 
0.3% HSA 
MDC-
induced 
chemotaxis 
6.3 ± 0.2 
(n=3) 
6.8 ± 0.2  
(n=3) 
Inhibition of Th2 
cell CCL17 driven 
chemotaxis in 
0.3% HSA 
TARC-
induced 
chemotaxis 
6.3 ± 0.1 
(n=3) 
6.5 (n=1) 
 
The anti-inflammatory effects of 47 were investigated in 
Brown-Norway rats sensitized to ovalbumin.  Sensitized 
rats were dosed orally (bid) with 47 at 0.22, 0.75, 2.2, 3.0, 
7.5 and 15 mol/kg 1 hour prior to antigen challenge and 
every 12 hours thereafter prior to termination 96 hours post 
challenge. Histopathological examination of the lung tis-
sue showed a marked, dose-dependent reduction in a 
 range of histological correlates with reduced alveolitis and 
leukocyte trafficking in the microvasculature being the 
most diagnostic features of efficacy. The changes were first 
visible at a dose of 0.22 mol/kg and maximal at 7.5 
mol/kg.  Plasma samples were taken 12 hours after the last 
dose of compound for measurement of terminal trough 
concentrations of 47 to demonstrate a strong PKPD corre-
lation (Table 7). 
Table 7 Terminal plasma concentrations of 47 
Dose 
(mol/kg)  
Total plasma  
concentration (M) 
Free plasma  
concentration/pIC50 
0.22 <LOQ* - 
0.75 <LOQ* - 
2.2 <LOQ* - 
3.0 0.033 ± 0.018 0.6 
7.5 0.14 ± 0.069 3 
15 0.49 ± 0.18 9 
*LOQ was 0.03 M for the 0.22, 0.75 and 2.2 mol/kg doses 
The synthesis of 47 and 49 is shown (Scheme 1). Dibro-
mination of 2-aminopyrazine followed by selective dis-
placement of the bromine in the 3-position with sodium 
methoxide gave 2-amino-5-bromo-3-methoxypyrazine. 
The bromine in the 5-position was then removed by hydro-
genation and coupling of the 2, 3-dichlorophenylsulphonyl 
chloride with 2-amino-3-methoxypyrazine afforded 47. A 
highly-selective 5-position nitration of 47 followed by re-
duction of the nitro group 52 gave an amino-pyrazine 53 
that was diazotized in the presence of hydrofluoric acid to 
give 49. 
 
Scheme 1.  i) Br2, dichloromethane, 2,6-lutidine (85-95%) 
ii) NaOMe (3 eq.), MeOH, reflux (90-95%) iii) H2, Pd/C, etha-
nol, rt (95%) iv) ArSO2Cl, KOtBu, 0-25°C, THF (80-95%) v) 
HNO3, AcOH, 70-85oC (75-82%) vi) H2, Pd/C, AcOH, 60oC (75-
92%) vii) HBF4, CH3CN, 0-5oC, NaNO2 (40%) or HF / Pyridine 
/ NaNO2 (85%). Range of percentage yields across multiple re-
actions and scale (~100 mg to >50g). 
In summary, a new series of potent and bioavailable 
amino-pyrazine sulfonamide CCR4 receptor antagonists 
have been developed from a lead optimization program in-
itiated from a high-throughput screening / synthesis cam-
paign. The initial hit series proved to have reasonable ac-
tivity but was hindered by having very high human plasma 
protein binding resulting in a low free fraction of com-
pound.  Through chemical modification, both the potency 
of the series and the free fraction was enhanced to ulti-
mately deliver two clinical candidates. Further studies on 
these compounds will be reported in due course. 
Supporting Information 
Representative synthetic procedures and analytical data for 47 
and 49. Description of biological assay (CCR4 receptor antag-
onism using FMAT whole cell binding). 
 
The Supporting Information is available free of charge on the 
ACS Publications website. 
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